Target intelligence / Profile preview

Dengue virus non-structural protein 5 (NS5) (NS5)

Target
NS5
Molecular classification
Enzyme, RNA polymerase, Transferase, Viral non-structural protein
01

Overview

The Dengue virus non-structural protein 5 (NS5) is a highly conserved, multifunctional enzyme that serves as the primary catalytic driver of the viral replication cycle [2, 11]. It consists of two essential domains: an N-terminal methyltransferase (MTase) responsible for viral RNA capping and a C-terminal RNA-dependent RNA polymerase (RdRp) that synthesizes the viral RNA genome [14, 17]. These activities are crucial for the production of new viral genetic material and for protecting viral RNA from detection by the host's innate immune system [11, 22]. NS5 functions within a large replication complex on the endoplasmic reticulum membranes of infected cells, where it interacts with other viral proteins such as the NS3 protease-helicase and NS4B to coordinate replication and assembly [6, 8, 21]. Given its vital role and the absence of a direct human homolog, NS5 is a premier target for direct-acting antivirals, including nucleoside and non-nucleoside inhibitors [12, 15, 19]. Successful therapeutic intervention requires achieving broad-spectrum efficacy across all four distinct Dengue virus serotypes while avoiding off-target effects on host cell polymerases [10, 11, 24].

Other names
Dengue virus replicationDENV replication complexDengue virus RNA-dependent RNA polymeraseDENV NS5Dengue virus RdRpDengue virus methyltransferase
02

Mechanism of action

Inhibition of RNA-dependent RNA polymerase activity, inhibition of viral RNA methyltransferase activity, antagonism of NS4B protein within the replication complex, and inhibition of viral polyprotein processing.

03

Biological functions

Viral RNA replicationRNA cappingViral protein synthesisImmune response modulationPolyprotein processing
04

Disease associations

InfectionDengue feverDengue hemorrhagic feverDengue shock syndrome
05

Safety considerations

Potential mitochondrial toxicity due to off-target inhibition of host RNA polymerasesRapid development of drug-resistant viral mutationsComplexity of achieving pan-serotype efficacy against DENV-1, 2, 3, and 4Risk of sub-therapeutic doses potentially influencing antibody-dependent enhancement (ADE)
06

Interacting drugs

Balapiravir (R1626)

7 more in the full profile.

07

Biomarkers

DENV RNA viral loadNS1 antigen levelsPlatelet countHematocrit levelsAminotransferase levels

Beyond the preview

Go deeper on Dengue virus non-structural protein 5 (NS5) (NS5).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dengue virus non-structural protein 5 (NS5) (NS5).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call